Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma

European Journal of Nuclear Medicine

Volumn 23, Issue 6, 1996, Pages 690-692

  Görres, Gerhard ^a,b   Kaim, Achim ^a   Otte, Andreas ^a   Götze, Maik ^a   Müller Brand, Jan ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Bone mineral density drug effects; Osteoporosis epidemiology; Thyroid carcinoma drug therapy; Thyroxine therapeutic use

Indexed keywords

LIOTHYRONINE; LIOTHYRONINE SODIUM; THYROXINE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIP; HORMONE SUBSTITUTION; HUMAN; LABORATORY TEST; LIOTHYRONINE BLOOD LEVEL; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; RISK FACTOR; THYROID CARCINOMA; THYROXINE BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY; CARCINOMA; CASE-CONTROL STUDIES; FEMALE; HIP; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; POSTMENOPAUSE; PREMENOPAUSE; RISK FACTORS; THYROID NEOPLASMS; THYROTROPIN; THYROXINE;

EID: 0029938448     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00834532     Document Type: Article

References (9)

1. Riggs BL, Melton LJ III. Involutionul osteoporosis. N Engl J Med 1986; 314: 1676-1686.
2. Samaan NA, Maheshwari YK, Neder S, et al. Impact of therapy for differentiated carcinoma of the thyroid: an analysis of 706 cases. J Clin Endocrinol Metab 1983; 56: 1131-1138.
3. Diamond T, Nery L, Hales I. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce hone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab 1991; 72: 1184-1188.
4. Richelson LS, Wahner HW, Melton LJ III, Riggs BL. Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med 1984; 311: 1273-1275.
5. McDermott MT. Kidd GS, Blue P, Ghead V, Hofeldt FD. Reduced bone mineral content in totally thyroidectomized patients: possible effect of calcitonin deficiency [abstract]. J Clin Endocrinol Metab 1983; 369: 479.
6. Hall ML, Heavens J, Ell PJ. Variation between femurs as measured by dual energy X-ray absorptiometry (DEXA). Eur J Nucl Med 1991; 18: 38-40.
7. Florkowski CM, Brownlie BE, Elliot JR, Ayling EM, Turner JG. Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma. N Z Med J 1993; 106: 443-444.
8. Stall GM, Harris S, Sokoll LJ, Dawson-Hughes B. Accelerated bone loss in hypothyroid ptients overtreated with L-thyroxine. Ann Intern Med 1991; 113: 265-269.
9. Franklyn JA, Betteridge J, Daykin J, Holder R, Oates GD, Parle JV, Heath DA, Sheppard MC. Long-term thyroxine treatment and bone mineral density. Lancet 1992; 340: 435-437.